首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   9489篇
  免费   676篇
  国内免费   33篇
耳鼻咽喉   116篇
儿科学   224篇
妇产科学   260篇
基础医学   1431篇
口腔科学   169篇
临床医学   1110篇
内科学   1898篇
皮肤病学   207篇
神经病学   972篇
特种医学   316篇
外科学   1093篇
综合类   83篇
一般理论   1篇
预防医学   811篇
眼科学   126篇
药学   670篇
中国医学   41篇
肿瘤学   670篇
  2024年   11篇
  2023年   93篇
  2022年   207篇
  2021年   400篇
  2020年   260篇
  2019年   279篇
  2018年   317篇
  2017年   234篇
  2016年   297篇
  2015年   341篇
  2014年   397篇
  2013年   531篇
  2012年   764篇
  2011年   782篇
  2010年   440篇
  2009年   386篇
  2008年   618篇
  2007年   549篇
  2006年   545篇
  2005年   534篇
  2004年   438篇
  2003年   397篇
  2002年   361篇
  2001年   79篇
  2000年   61篇
  1999年   56篇
  1998年   77篇
  1997年   49篇
  1996年   37篇
  1995年   38篇
  1994年   37篇
  1993年   26篇
  1992年   32篇
  1991年   24篇
  1990年   27篇
  1989年   25篇
  1988年   33篇
  1987年   22篇
  1986年   25篇
  1985年   22篇
  1984年   26篇
  1983年   19篇
  1982年   27篇
  1980年   14篇
  1979年   20篇
  1978年   23篇
  1975年   19篇
  1973年   20篇
  1972年   14篇
  1971年   14篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
81.
目的为了研究宜昌市夷陵区0~6岁儿童维生素D营养状况及其与年龄、性别、季节之间的关系,以便为夷陵区儿童合理补充维生素D提供科学依据。方法对2017年1月至2018年7月来夷陵区妇幼保健院体检的0~6岁11656例儿童,采用荧光免疫层析方法进行末梢血25-(OH)D 3水平检测。结果该区11656例儿童末梢血25-(OH)D 3水平为(29.35±7.59)ng/mL,其中维生素D缺乏组566例(4.86%),维生素D不足组6579例(56.44%),维生素D充足组4511例(38.70%)。1岁以内婴儿组维生素D水平明显高于幼儿组和学龄前组,3岁以后儿童维生素D水平明显下降,各年龄组间差异有统计学意义(χ2=145.846,P<0.05)。不同季节儿童维生素D水平春季最高,冬季最低(χ2=504.007,P<0.05)。不同性别间儿童维生素D水平差异并无统计学意义(t=0.841,P>0.05)。结论我区0~6岁儿童维生素D水平大部分处于不足的状态,应增加该区儿童维生素D的摄入量,尤其加强学龄前组儿童维生素D的补充及冬季户外活动。  相似文献   
82.
83.
Abdominal aortic aneurysm (AAA) is a dilatation of the infra-renal abdominal aorta to greater than 3 cm. Population screening is offered to men in the year of their 65th birthday in the UK. Patients with small, asymptomatic AAAs (<5.5 cm) are entered into surveillance programmes and have their cardiovascular risk factors managed aggressively. An AAA ≥5.5 cm diameter, or one which is symptomatic, should be considered for surgical repair to prevent rupture. Aneurysm repair can be undertaken using either an open surgical or endovascular approach; the decision should be tailored to the individual patient and made by the surgeon and patient, with input from a multi-disciplinary team.  相似文献   
84.
Introduction It has been demonstrated that urinary neutrophil gelatinase-associated lipocalin (NGAL) and calprotectin are helpful biomarkers in the differentiation of intrinsic and prerenal acute kidney injury.Objective The present cross-sectional study investigates, whether urinary biomarkers are able to differentiate primarily inflammatory from non-inflammatory entities in chronic kidney disease (CKD).Methods Urinary calprotectin, NGAL, and kidney injury molecule-1 (KIM-1) concentrations were assessed in a study population of 143 patients with stable CKD and 29 healthy controls. Stable renal function was defined as an eGFR fluctuation ≤5 ml/min/1.73 m2 in the past 12 months. Pyuria, metastatic carcinoma, and renal transplantation were regarded as exclusion criteria. Diabetic nephropathy, hypertensive nephropathy, and polycystic kidney disease were categorized as ‘primarily non-inflammatory renal diseases’ (NIRD), whereas glomerulonephritis and vasculitis were regarded as ‘primarily inflammatory renal diseases’ (IRD).Results Urinary calprotectin and NGAL concentrations significantly differed between CKD and healthy controls (p < 0.05 each), whereas KIM-1 concentrations did not (p = 0.84). The three biomarkers did neither show significant differences in-between the individual entities, nor the two categories of IRD vs. NIRD (calprotectin 155.7 vs. 96.99 ng/ml; NGAL 14 896 vs. 11 977 pg/ml; KIM-1 1388 vs. 1009 pg/ml; p > 0.05 each). Albumin exceeds the diagnostic power of the investigated biomarkers by far.Conclusions The urinary biomarkers calprotectin, NGAL, and KIM-1 have no diagnostic value in the differentiation of primarily inflammatory vs. non-inflammatory etiologies of CKD.  相似文献   
85.
Epstein–Barr virus (EBV) reactivation is a very common and potentially lethal complication of renal transplantation. However, its risk factors and effects on transplant outcome are not well known. Here, we have analysed a large, multi-centre cohort (N = 512) in which 18.4% of the patients experienced EBV reactivation during the first post-transplant year. The patients were characterized pre-transplant and two weeks post-transplant by a multi-level biomarker panel. EBV reactivation was episodic for most patients, only 12 patients showed prolonged viraemia for over four months. Pre-transplant EBV shedding and male sex were associated with significantly increased incidence of post-transplant EBV reactivation. Importantly, we also identified a significant association of post-transplant EBV with acute rejection and with decreased haemoglobin levels. No further severe complications associated with EBV, either episodic or chronic, could be detected. Our data suggest that despite relatively frequent EBV reactivation, it had no association with serious complications during the first post-transplantation year. EBV shedding prior to transplantation could be employed as biomarkers for personalized immunosuppressive therapy. In summary, our results support the employed immunosuppressive regimes as relatively safe with regard to EBV. However, long-term studies are paramount to support these conclusions.  相似文献   
86.
Annals of Surgical Oncology - Black women with breast cancer have a worse overall survival compared with White women; however, no difference in Oncotype DX? (ODX) recurrence scores has been...  相似文献   
87.
Objectifying donor lung quality is difficult and currently there is no consensus. Several donor scoring systems have been proposed in recent years. They all lack large-scale external validation and widespread acceptance. A retrospective evaluation of 2201 donor lungs offered to the lung transplant program at the Medical University of Vienna between January 2010 and June 2018 was performed. Five different lung donor scores were calculated for each offer (Oto, ET, MALT, UMN-DLQI, and ODSS). Prediction of organ utilization, 1-year graft survival, and long-term outcome were analyzed for each score. 1049 organs were rejected at the initial offer (group I), 209 lungs declined after procurement (group II), and 841 lungs accepted and transplanted (group III). The Oto score was superior in predicting acceptance of the initial offer (AUC: 0.795; CI: 0.776–0.815) and actual donor utilization (AUC: 0.660; CI: 0.618–0.701). Prediction of 1-year graft survival was best using the MALT score, Oto score, and UMN-DLQI. Stratification of early outcome by MALT was significant for length of mechanical ventilation (LMV), PGD3 rates, ICU stay and hospital stay, and in-hospital-mortality, respectively. To the best of our knowledge, this study is the largest validation analysis comparing currently available donor scores. The Oto score was superior in predicting organ utilization, and MALT score and UMN-DLQI for predicting outcome after lung transplantation.  相似文献   
88.
Posttransplant lymphoproliferative disorder (PTLD) is a serious complication of solid organ transplantation (SOT). Most PTLD cases are associated with Epstein–Barr virus (EBV) infection. The role of antiviral prophylaxis or rituximab therapy for prevention of PTLD in SOT recipients is controversial. In a nationwide cohort, we assessed the incidence, presentation, and outcome of histologically proven PTLD. We included 4765 patients with a follow-up duration of 23 807 person-years (py). Fifty-seven PTLD cases were identified; 39 (68%) were EBV positive (EBV+ PTLD). Incidence rates for EBV+ PTLD at 1, 2, and 3 years posttransplant were 3.51, 2.24, and 1.75/1000 py and 0.44, 0.25, and 0.29/1000 py for EBV− PTLD. We did not find an effect of antiviral prophylaxis on early and late EBV+ PTLD occurrence (early EBV+ PTLD: SHR 0.535 [95% CI 0.199–1.436], p = .264; late EBV+ PTLD: SHR 2.213, [95% CI 0.751–6.521], p = .150). However, none of the patients (0/191) who received a rituximab-containing induction treatment experienced PTLD, but 57 of 4574 patients without rituximab induction developed PTLD. In an adjusted restricted mean survival time model, PTLD-free survival was significantly longer (0.104 years [95% CI 0.077–0.131]) in patients receiving rituximab as induction treatment. This study provides novel data on the association of rituximab induction and reduced risk for PTLD.  相似文献   
89.
Journal of Community Health - Tattoos of formerly gang-involved and incarcerated individuals can negatively impact their ability to reintegrate into society. Laser tattoo removal is essential to...  相似文献   
90.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号